

Press release from Emotra AB (publ)

Göteborg, July 10, 2015

## Thorell presents EDOR in the US this autumn

**Lars-Håkan Thorell, the creator behind Emotra's EDOR method to evaluate the risk of suicide, is presenting his research and discoveries at a major international conference in the US this autumn; IASR/AFSP International Summit on Suicide Research, 11-14 October 2015, Waldorf Astoria Hotel, New York City, Preventing Suicide: Progress through Research. Over 450 patients have now been tested in the ongoing multi-centre study.**

Ever since Professor Marco Sarchiapone's visit to the US, where he was given the opportunity to present EDOR and the ongoing European multi-centre study, interest in the method has grown in the US. In October, Lars-Håkan Thorell will present the method, the earlier research and the ongoing multi-centre study as part of a major and important international conference organised by two leading organisations in the field: the International Academy of Suicide Research and the American Foundation for Suicide Prevention. The conference brings together many of the world's foremost researchers in the field of suicide.

Emotra's main focus, however, is to carry out the ongoing multi-centre study and to work with participating clinics in reaching consensus on the method's safety, efficacy, reliability and reproducibility. Once this consensus has been reached, the product will be launched in Europe. If increased interest from the Americans contributes to US clinics wanting to conduct their own studies, and there are realistic prospects for completing them, then Emotra has no objection to starting these studies even before the European launch begins.

The multi-centre study, conducted in collaboration between Emotra and the European Psychiatric Association's Section on Suicidology, will continue to run as planned and Emotra has now analysed EDOR test data from over 450 patients. After the issues with transferring data that arose in the autumn, no further obstacles or technical problems have occurred. The method works entirely according to expectations and the clinics have not experienced any difficulties in using the test.

On 16-18 September, the majority of the clinics will meet in Rome for joint deliberations on the method, the clinical protocol and the current situation of the study as well as prospects for continued work. The meeting is organised by Professor Marco Sarchiapone, who is also organising a research conference for young suicide researchers within the framework of the European Psychiatric Association's Section on Suicidology. The research conference will start immediately after the EDOR meeting has finished. In this way, the next generation of scientists in the field will have the opportunity of hearing about EDOR right from the start.

Regarding the conference, Professor Sarchiapone says:

---

***Emotra AB (publ)** is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.*



*"In my mind, it is an ideal situation that we are able to introduce EDOR to the young scientist already now. We want them to know that there is an ongoing study on a risk evaluation method and that the purpose with the study is to demonstrate that a reliable instrument could be used in order to better identify patients at risk for suicide. Still the professional expertise will be responsible for the final clinical judgement but their work will be supported by a quantitative and accurate measurement. In this way EDOR has the potential to become an important complement to the professionals' work."*

On 29-30 September, Emotra's CEO, Claes Holmberg, will present the company and the EDOR method in conjunction with the 21st MedTech Investing Europe Conference, The King's Fund, London, UK.

**For further information, please contact:**

*Claes Holmberg, CEO  
Telephone: +46 708 25 45 47  
E-mail: [claes@emotra.se](mailto:claes@emotra.se)*

---

**Emotra AB (publ)** is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden  
Tel: +46 708 25 45 47, [www.emotra.se](http://www.emotra.se)